NCT00851045 2015-10-12
Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer
Bristol-Myers Squibb
Phase 2 Completed
Bristol-Myers Squibb
Adnexus, A Bristol-Myers Squibb R&D Company